Replicate Bioscience
PrivateLast Round
Grant
Jun 19, 2026
Total Funding Raised
$49M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Replicate Bioscience is a biotechnology company that develops self-replicating RNA (srRNA) immunotherapies for the treatment of cancer, infectious diseases, and autoimmune disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Replicate Bioscience Comparables
Compare Replicate Bioscience with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Chimeron Bio | 83% | |
| Strand Therapeutics | 83% | |
| Bristol Myers Squibb | 82% |
Replicate Bioscience Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jun 19, 2026 | ||||
| Series A | Sep 8, 2021 | ||||
| Seed | Feb 16, 2021 | ||||
| Seed | Jun 24, 2020 |
Key People
Founding team and executive leadership
Replicate Bioscience Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Apple Tree Partners | Series A, Seed |
| Gates Foundation | Grant |
| Bill & Melinda Gates Foundation | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 8, 2026
Secured $7M in grant funding.
- Jan 8, 2026
Developing self-replicating RNA vaccines for HIV and malaria.
Replicate Bioscience Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Replicate Bioscience's valuation, stock price, and market status.
Is Replicate Bioscience a public or private company?
Replicate Bioscience is a private company.
What is the current stock price of Replicate Bioscience?
Replicate Bioscience is a private company with no public stock price. No recent secondary market data is available.
How much is Replicate Bioscience worth (valuation)?
Valuation information for Replicate Bioscience is not publicly available.
Can I buy Replicate Bioscience stock?
Replicate Bioscience shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Replicate Bioscience's last funding round?
Replicate Bioscience's most recent funding round was Grant on January 8, 2026.
Who are the main investors in Replicate Bioscience?
Key investors in Replicate Bioscience include Apple Tree Partners.
Will Replicate Bioscience IPO soon?
No public IPO plans have been announced for Replicate Bioscience.
How can I track Replicate Bioscience secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Replicate Bioscience's secondary market activity and sign up for updates.